Mineralys Therapeutics Announces JAMA Publication of Full Ta

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure with a well-tolerated profile – – Enhanced reduction...

Related Keywords

Radnor , Pennsylvania , United States , American , Tanabe Pharma , Catalys Pacific , Luke Laffin , David Rodman , Tom Weible , Nasdaq , Mineralys Therapeutics Inc , Elixir Health Public Relations , Drug Administration , Vascular Thoracic Institute , Twitter , Journal Of The American Medical Association , Exchange Commission , Globenewswire Inc , American Medical Association , Blood Pressure Disorders , Thoracic Institute , Chief Medical Officer , Mineralys Therapeutics , States Food , Private Securities Litigation Reform Act , Markets ,